Spironolactone Dosing for Heart Failure
Start spironolactone at 25 mg once daily for heart failure with reduced ejection fraction (HFrEF), then titrate to a target dose of 50 mg once daily after 4-8 weeks if tolerated.
Initial Dosing Algorithm
Standard initiation (eGFR >50 mL/min/1.73m² and K+ ≤5.0 mEq/L):
Reduced renal function (eGFR 30-50 mL/min/1.73m²):
- Start at 25 mg every other day or 12.5 mg daily 1, 2
- More frequent monitoring required due to hyperkalemia risk
Target Dose Titration
After 4-8 weeks, if potassium remains ≤5.5 mmol/L and creatinine stable:
- Increase to 50 mg once daily 3, 4, 3
- This is the evidence-based target dose from the RALES trial 3
- Recheck potassium and creatinine 1 and 4 weeks after dose increase 4
The 2013 ACC/AHA guidelines 1 and FDA labeling 2 align with this approach, confirming 25 mg daily as the starting dose with titration to 50 mg daily as the maintenance target.
Who Should Receive Spironolactone
Mandatory criteria:
- LVEF ≤35% (ESC) or ≤40% (ACC/AHA) 3, 1
- NYHA class III-IV symptoms 3, 4
- Already on optimal doses of ACE inhibitor (or ARB) AND beta-blocker 3, 4
- Potassium <5.0 mEq/L 1
- Creatinine ≤2.5 mg/dL (men) or ≤2.0 mg/dL (women), or eGFR >30 mL/min/1.73m² 1
Critical exclusion: Do NOT use spironolactone if patient is on both an ACE inhibitor AND an ARB simultaneously 3, 4
Monitoring Schedule
First 3 months:
After stabilization:
Managing Adverse Effects
Hyperkalemia management:
- K+ 5.5-6.0 mmol/L: Reduce dose to 25 mg every other day 3, 4
- K+ ≥6.0 mmol/L: Stop immediately and monitor closely 3, 4
Worsening renal function:
- Creatinine 2.5-3.5 mg/dL (220-310 mmol/L): Reduce to 25 mg every other day 3, 4
- Creatinine >3.5 mg/dL (>310 mmol/L): Stop immediately 3, 4
Gynecomastia: Switch to eplerenone (same dosing: start 25 mg, target 50 mg daily) 3, 4
Evidence Base and Mortality Benefit
The RALES trial demonstrated that spironolactone 25-50 mg daily reduced:
This mortality benefit was achieved with a mean dose of 26 mg daily in the trial 2, supporting that even doses below the 50 mg target remain effective if higher doses cannot be tolerated 5.
Common Pitfalls
Do not use higher doses than 50 mg daily for chronic HFrEF. While research studies have explored 60-80 mg daily 6, 7, these are not guideline-recommended and substantially increase hyperkalemia risk without established long-term safety data. The evidence-based target remains 50 mg daily 3, 4, 1.
Do not discontinue for minor potassium elevations. Dose reduction to every-other-day dosing is preferred over complete discontinuation, as stopping spironolactone increases subsequent cardiovascular events 2-4 fold 5. Even low doses (15-25 mg daily) provide clinical benefit 5.
Monitor more frequently in elderly patients and those with baseline eGFR 30-50 mL/min/1.73m², as these groups experience higher discontinuation rates (up to 30% in first year) 5 and require more cautious titration.